Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug
By Connor Hart
Shares of Invivyd were higher after the company said the Food and Drug Administration cleared its investigational new drug application, as well as provided feedback to advance its drug that aims to prevent Covid.
The stock rose 13% to $1.31 in premarket trading Monday. Through Friday's close, shares have more than doubled so far this year.
Invivyd is developing VYD2311, a vaccine-alternative antibody to prevent Covid. The program will undergo testing, with separate studies set to compare the safety and efficacy of VYD2311 with placebo, as well as place VYD2311 in a head-to-head trial against an mRNA-based Covid vaccine.
The company said it intends to initiate these clinical trials as soon as practicable, aiming for the trails to start before the end of the year, with top-line data by mid-2026.
"We are moving as fast as possible to bring Americans a new choice in protection from Covid," Chairman Marc Elia said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
October 06, 2025 08:39 ET (12:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States